Document is current
Any future updates will be listed below
-
Authors
Fiorenza, S. https://orcid.org/0000-0003-4432-2215
Zheng, Y. https://orcid.org/0000-0002-8806-2761
Purushe, J.
Bock, T. J. https://orcid.org/0009-0006-3744-0466
Sarthy, J. https://orcid.org/0000-0001-5244-7865
Janssens, D. H. https://orcid.org/0000-0003-1079-9525
Sheih, A. S.
Kimble, E. L. https://orcid.org/0000-0002-1885-1773
Kirchmeier, D.
Phi, T. D.
Gauthier, J. https://orcid.org/0000-0002-5769-8409
Hirayama, A. V. https://orcid.org/0000-0001-7980-3882
Riddell, S. R.
Wu, Q. https://orcid.org/0000-0002-2292-4816
Gottardo, R. https://orcid.org/0000-0002-3867-0232
Maloney, D. G.
Yang, J. Y. H. https://orcid.org/0000-0002-5271-2603
Henikoff, S. https://orcid.org/0000-0002-7621-8685
Turtle, C. J.
-
Funding
Funding for this research was provided by:
Haematology Society of Australia and New Zealand (Clinical Fellowship Grant)
- License Information
-
More Information
Article History
Received: 17 January 2024
Accepted: 11 September 2024
First Online: 27 September 2024
Competing interests
: S.F. has filed and received license fees on patents for optimising CAR T cell function, has received research laboratory grants from Bristol Myers Squibb, and has consulted ad hoc for Prescient Therapeutics. E.L.K. receives research support from Juno Therapeutics, a BMS company. A.S.S. is a current employee of Umoja Biopharma. A.V.H. has received research funding from Juno Therapeutics, a Bristol Myers Squibb Company, and Nektar Therapeutics; it has received honoraria from Bristol Myers Squibb. J.G. reports honoraria from EUSA Pharma, JMP, Larvol, and Multerra Bio; serves on scientific advisory boards for Legend Biotech, Janssen, Kite (a Gilead company), and MorphoSys; and receives research funding from Sobi, Juno Therapeutics, Celgene (a BMS company), and Angiocrine Bioscience. S.R.R. is a cofounder and adviser to Lyell Immunopharma; has research funding from and intellectual property licensed to Lyell Immunopharma; was a cofounder of Juno Therapeutics; is an inventor of patents licensed to Juno Therapeutics; and served as an adviser to Juno Therapeutics and Adaptive Biotechnologies. D.G.M. has received research funding from Juno Therapeutics, a Bristol Myers Squibb Company, Celgene, and Kite Pharma, a Gilead company; has served on ad hoc advisory board meetings from Amgen, BMS, Genentech, Gilead, Incyte, Janssen, Legend Biotech, Mustang Bio, MorphoSys, Novartis, Pharmacyclics, and Umoja; has rights to receive royalties from Fred Hutch for patents licensed to Juno Therapeutics; serves on scientific advisory board with stock options and compensations for A2 Biotherapeutics and Navan Technologies. S.H. has filed patent applications on related work. C.J.T. received research funding from Juno Therapeutics/BMS, Nektar Therapeutics, and Nanostring; serves on Scientific Advisory Boards for Caribou Biosciences, T-CURX, Myeloid Therapeutics, ArsenalBio, Cargo Therapeutics, Celgene/BMS Cell Therapy, Differentia Bio, eGlint, and Advesya; is a DSMB member for Kyverna; has served on ad hoc advisory roles/consulting (last 12 months) for Prescient Therapeutics, Century Therapeutics, IGM Biosciences, Abbvie, Boxer Capital, Novartis; holds stock options for Eureka Therapeutics, Caribou Biosciences, Myeloid Therapeutics, ArsenalBio, Cargo Therapeutics, and eGlint; and has the right to receive payment from Fred Hutch Cancer Center as an inventor on patents related to CAR T-cell therapy. The remaining authors declare no competing interest.
